A Placebo Controlled Study of the Impact on Insulin Sensitivity and Lipid Profile of Maraviroc 300 mg Twice Daily in HIV Negative Male Volunteers.
Phase of Trial: Phase I
Latest Information Update: 13 Aug 2010
At a glance
- Drugs Maraviroc (Primary)
- Indications HIV infections; HIV-1 infections
- Focus Pharmacodynamics
- 13 Aug 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 07 Dec 2009 Results were presented at the 12th European AIDS Conference.
- 25 Oct 2008 New trial record.